CR20110225A - Composición estabilizada para el tratamiento de la psoriasis - Google Patents

Composición estabilizada para el tratamiento de la psoriasis

Info

Publication number
CR20110225A
CR20110225A CR20110225A CR20110225A CR20110225A CR 20110225 A CR20110225 A CR 20110225A CR 20110225 A CR20110225 A CR 20110225A CR 20110225 A CR20110225 A CR 20110225A CR 20110225 A CR20110225 A CR 20110225A
Authority
CR
Costa Rica
Prior art keywords
psoriasis
treatment
stabilized composition
alkyl
carboxylic ester
Prior art date
Application number
CR20110225A
Other languages
English (en)
Inventor
William Shifeng Wei
Yiping Wang
Jianzhen Pan
Sung Hi Jo
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of CR20110225A publication Critical patent/CR20110225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un ungüento estable al almacenamiento del presente invento que comprende un compuesto de vitamina D, un corticosteroide, y un alquilamino substituido de N,N-di(C1-C8) , un éster carboxílico(C2-C18) alquilo de (C4-C18) un éster carboxílico (C8-C22) alquilo de-(C1-C4)-en una base de ungüento de petrolato y opcionalmente conteniendo aceite mineral, y/o tocoferol.
CR20110225A 2008-10-03 2011-04-29 Composición estabilizada para el tratamiento de la psoriasis CR20110225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19512608P 2008-10-03 2008-10-03

Publications (1)

Publication Number Publication Date
CR20110225A true CR20110225A (es) 2011-07-18

Family

ID=42073781

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110225A CR20110225A (es) 2008-10-03 2011-04-29 Composición estabilizada para el tratamiento de la psoriasis

Country Status (18)

Country Link
US (2) US9220701B2 (es)
EP (1) EP2343978A4 (es)
JP (1) JP5667060B2 (es)
KR (1) KR20110067145A (es)
CN (1) CN102202509A (es)
AU (1) AU2009300331A1 (es)
BR (1) BRPI0920728A2 (es)
CA (1) CA2739376A1 (es)
CL (1) CL2011000722A1 (es)
CR (1) CR20110225A (es)
EC (1) ECSP11011022A (es)
IL (1) IL212062A0 (es)
MX (1) MX2011003568A (es)
NZ (1) NZ592300A (es)
PE (1) PE20110849A1 (es)
RU (1) RU2526162C2 (es)
WO (1) WO2010039251A1 (es)
ZA (1) ZA201103061B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592300A (en) * 2008-10-03 2013-01-25 Nexmed Holdings Inc Stabilized composition for treating psoriasis
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
WO2014028780A2 (en) * 2012-08-15 2014-02-20 Nexmed Holdings, Inc. Antifungal compounds and methods of use
CN105784902A (zh) * 2016-03-11 2016-07-20 重庆华邦制药有限公司 低浓度丁酸氯倍他松的检测方法
EP3456314A1 (en) 2017-09-14 2019-03-20 Tiofarma B.V. Topical formulation comprising 17-ketolic corticosteroid
US20210196631A1 (en) * 2018-08-28 2021-07-01 Glenmark Pharmaceuticals Limited Container system and pharmaceutical foam composition comprising betamethasone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
TR200101790T2 (tr) 1998-12-23 2001-10-22 Idea Ag. Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
HU230045B1 (hu) 1999-04-23 2015-06-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Bőrgyógyászati alkalmazásra szolgáló nem vizes gyógyszerkészítmény
JP2006511545A (ja) 2002-12-17 2006-04-06 ガルデルマ・ソシエテ・アノニム カルシトリオール及びプロピオン酸クロベタゾールの組み合わせ物を含む医薬組成物
DK1635770T3 (da) * 2003-03-21 2009-08-03 Nexmed Holdings Inc Antifungal neglelak og anvendelsesmetode
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
FR2871696B1 (fr) * 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
CA2633489C (en) * 2005-12-14 2013-09-24 Zars Pharma, Inc. Compositions and methods for treating dermatological conditions
US7560489B2 (en) 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
NZ592300A (en) * 2008-10-03 2013-01-25 Nexmed Holdings Inc Stabilized composition for treating psoriasis

Also Published As

Publication number Publication date
CL2011000722A1 (es) 2012-01-20
ZA201103061B (en) 2012-04-25
RU2011117230A (ru) 2012-11-10
US20110237558A1 (en) 2011-09-29
US9220701B2 (en) 2015-12-29
KR20110067145A (ko) 2011-06-21
NZ592300A (en) 2013-01-25
ECSP11011022A (es) 2011-06-30
BRPI0920728A2 (pt) 2015-08-18
JP2012504607A (ja) 2012-02-23
US20160067266A1 (en) 2016-03-10
PE20110849A1 (es) 2011-12-02
CN102202509A (zh) 2011-09-28
AU2009300331A1 (en) 2010-04-08
IL212062A0 (en) 2011-06-30
RU2526162C2 (ru) 2014-08-20
EP2343978A1 (en) 2011-07-20
CA2739376A1 (en) 2010-04-08
MX2011003568A (es) 2011-06-09
EP2343978A4 (en) 2013-11-27
WO2010039251A1 (en) 2010-04-08
JP5667060B2 (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
CR20110225A (es) Composición estabilizada para el tratamiento de la psoriasis
CU20160100A7 (es) Mezclas y composiciones fungicidas sinérgicas que comprenden 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2(1h)-ona e inhibidores de la biosíntesis de esterol fungicida para el control fúngico
CU20150120A7 (es) Compuestos y composiciones orgánicas para la inhibición de fasn
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
NI201500120A (es) Compuestos de biaril - amida como inhibidores de cinasa
GT201100322A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
ECSP14004595A (es) 2-tiopirimidinonas
HN2010002121A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak
GT201000376A (es) Compuestos organicos
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
BRPI0915536A2 (pt) salicilatos acetilados de ácidos graxos e seus usos
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
AR089482A1 (es) Composicion antimicrobiana y metodo para prolongar la vida util del agua, alimentos/piensos o ingredientes de alimentos/piensos
EP2393353A4 (en) COMPOSITIONS AND METHODS OF ORGAN CONSERVATION
DOP2009000169A (es) Derivados ciclados como inhibidores de eg-5
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
GT201300263A (es) Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
BR112014010347A2 (pt) óleo contendo ácido graxo poliinsaturado oxidativamente estável
BR112022022409A2 (pt) 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3